CA2004261A1 - Interleukine-6 synthetique - Google Patents

Interleukine-6 synthetique

Info

Publication number
CA2004261A1
CA2004261A1 CA002004261A CA2004261A CA2004261A1 CA 2004261 A1 CA2004261 A1 CA 2004261A1 CA 002004261 A CA002004261 A CA 002004261A CA 2004261 A CA2004261 A CA 2004261A CA 2004261 A1 CA2004261 A1 CA 2004261A1
Authority
CA
Canada
Prior art keywords
peptide
protein
recombinant
gene
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002004261A
Other languages
English (en)
Inventor
Charles T. Tackney
Dana M. Fowlkes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina System
ImClone LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2004261A1 publication Critical patent/CA2004261A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5412IL-6
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/61Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002004261A 1988-12-01 1989-11-30 Interleukine-6 synthetique Abandoned CA2004261A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27869088A 1988-12-01 1988-12-01
US07/278,690 1988-12-01
US44062489A 1989-11-22 1989-11-22
US07/440,624 1989-11-22

Publications (1)

Publication Number Publication Date
CA2004261A1 true CA2004261A1 (fr) 1990-06-01

Family

ID=26959230

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002004261A Abandoned CA2004261A1 (fr) 1988-12-01 1989-11-30 Interleukine-6 synthetique

Country Status (8)

Country Link
EP (1) EP0446283A4 (fr)
JP (1) JPH04503301A (fr)
AU (1) AU639428B2 (fr)
CA (1) CA2004261A1 (fr)
GR (1) GR890100799A (fr)
IL (1) IL92525A0 (fr)
PT (1) PT92479A (fr)
WO (1) WO1990006370A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
ZA924674B (en) * 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
US5338833A (en) * 1992-07-23 1994-08-16 The University Of North Carolina At Chapel Hill Carboxy terminal IL-6 muteins
WO1994003492A1 (fr) * 1992-08-06 1994-02-17 The University Of Melbourne Variantes de l'interleukine-6 et leurs utilisations
US5338834A (en) * 1993-01-26 1994-08-16 Allelix Biopharmaceuticals Inc. Ultrapure human interleukin-6
DE69430369T2 (de) 1993-09-15 2002-10-17 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter alphavirus vektor
JPH093099A (ja) * 1995-06-20 1997-01-07 Toyobo Co Ltd マクロファージ刺激蛋白質改変体およびその製造法
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
US6265204B1 (en) 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP2292772A1 (fr) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
AU2003228751A1 (en) 2002-05-01 2003-11-17 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
CA2585672A1 (fr) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Approches combinatoires destinees a produire des reponses immunitaires
KR100692389B1 (ko) * 2005-04-21 2007-03-09 주식회사수산중공업 차압스위치
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2870238A4 (fr) 2012-07-05 2016-03-09 Ohio State Innovation Foundation Compositions et procédés associés à des vaccins viraux
WO2017040387A2 (fr) 2015-08-31 2017-03-09 Technovax, Inc. Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
EP3443107A1 (fr) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Systèmes de réplicon d'artérivirus recombinant et utilisations correspondantes
EP3526332B1 (fr) 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Système réplicon recombinant de virus et leurs utilisations
JP2020500536A (ja) 2016-12-05 2020-01-16 シンセティック ジェノミクス インコーポレーテッド 遺伝子発現増強のための組成物および方法
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
CN114805537A (zh) * 2022-04-26 2022-07-29 华南农业大学 一种表达犬白介素6的重组质粒、稳定表达犬白介素6蛋白的细胞株及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62102157A (ja) * 1985-10-30 1987-05-12 Chuzo Kishimoto 抗体
DE3750106T3 (de) * 1986-08-06 1999-04-22 Ajinomoto Co., Inc., Tokio/Tokyo Rekombinanter B-Zell-Differenzierungsfaktor.
IL85204A0 (en) * 1988-01-26 1988-07-31 Yeda Res & Dev Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
CA1341588C (fr) * 1988-01-26 2009-01-06 Michel Revel Ifn-beta2/i1-6, humain, sa purification et ses utilisations
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド

Also Published As

Publication number Publication date
GR890100799A (el) 1991-03-15
IL92525A0 (en) 1990-08-31
PT92479A (pt) 1990-06-29
WO1990006370A1 (fr) 1990-06-14
EP0446283A1 (fr) 1991-09-18
AU4801490A (en) 1990-06-26
AU639428B2 (en) 1993-07-29
JPH04503301A (ja) 1992-06-18
EP0446283A4 (en) 1992-01-08

Similar Documents

Publication Publication Date Title
AU639428B2 (en) Synthetic interleukin-6
US5629172A (en) Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US7635466B1 (en) DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides
EP0077670B1 (fr) Interféron humain immunisé
US4650674A (en) Synergistic cytotoxic composition
US5914254A (en) Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
JP2766621B2 (ja) 組み換えg−csf
EP0155549A2 (fr) ADN codant pour le facteur humain de nécrose de tumeur et le polypeptide du facteur humain de nécrose de tumeur
US5681720A (en) DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
JPH07308191A (ja) ハイブリド型ヒト白血球インタフェロンをコードするdna
HU208710B (en) Method for preparation of mammalian human il-4, dna encoding il-4, host cell and pharmaceutical composition comprising human il-4
JPS6140221A (ja) 腫瘍壊死因子
EP0161901B1 (fr) Séquences d'cADN de IL-1 humaine, codant des protéines biologiquement actives de IL-1 humaine
EA003942B1 (ru) Усеченный по амино-концу моноцитарный хемотаксический белок (mcp-2) и способы его использования
Yasueda et al. High-level direct expression of semi-synthetic human interleukin-6 in Escherichia coli and production of N-terminus met-free product
US4921699A (en) Polypeptides having interferon activity
EP0256424B1 (fr) Fragments homogènes recombinants d'interféron immunisant et compositions pharmaceutiques les contenant
US4816566A (en) Polypeptides having interferon activity
Seow et al. Bacterial expression, facile purification and properties of recombinant human lymphotoxin (tumor necrosis factor beta)
AU621051B2 (en) Method for purifying granulocyte-macrophage colony stimulating factor
EP0207165A1 (fr) Vecteur de secretion de polypeptides, micro-organismes transformes par ledit vecteur, et procede de preparation de polypeptides avec lesdits micro-organismes
JPH02195888A (ja) ヒトインターロイキン2活性を有するポリペプチドをコードする遺伝子を含有する組換えdna体および該組換えdna体により形質転換された原核生物細胞
AU633278B2 (en) Isolation and cloning of complementary dna for gene coding of bovine trophoblast protein-1
KR890001828B1 (ko) 인터페론-α형의 폴리펩티드의 제조방법
US5081020A (en) Expression vectors containing λPL promoter, T1 T2 rRNA termination sequence and origin of replication derived from a constitutive high copy number plasmid hosts and related methods

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19950531